Skip to main content
Publications
Layton JB , Peetluk L, Wong HL, Jiao Y, Djibo DA, Bui C , Lloyd PC, Gruber JF, Miller M, Ogilvie RP, Deng J, Parambi R, Song J, Weatherby LB, Lo AC, Matuska K, Wernecke M, Clarke TC, Cho S, Bell EJ, Seeger JD, Yang GW, Illei D, Forshee RA, Anderson SA, McMahill-Walraven CN, Chillarige Y, Amend KL, Anthony M , Shoaibi A. Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States . Vaccine-X. 2024 Jan. doi: 10.1016/j.jvacx.2024.100447
Mellott CE, Jaworski R, Carrico J , Talbird SE , Dobrowolska I, Golicki D, Bencina G, Clinkscales M, Karamousouli E, Eiden AL, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland . Expert Rev Vaccines. 2023 Dec;22(11):1114-25. doi: 10.1080/14760584.2023.2275712
Shamarina D, Sluga-O'Callaghan M , Kassianos G, Marijam A, Dave V, Davenport E , Andani A, Curran D, Dewda P, Steffen R. Knowledge, attitudes, and practices of European healthcare professionals towards hepatitis A and hepatitis B vaccination in at-risk adults . Vaccines-Basel. 2023 Oct 26;11(1645):1-19. doi: 10.3390/vaccines11111645
Carrico J , Mellott CE, Talbird SE , Bento-Abreu A, Merckx B, Vandenhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Eiden A, Nyaku MK, Bencina G. Public health impact and return on investment of Belgium's pediatric immunization program . Front Public Health. 2023 Jun 22;11:1032385. doi: 10.3389/fpubh.2023.1032385
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C , Wilson M . Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England & Wales, Israel, and the United States . Infect Dis Ther. 2023 May;12(5):1351-64. doi: 10.1007/s40121-023-00798-x
Talbird S , Graham J , Anderson S , Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Cost-effectiveness and epidemiological impact of a novel 3-antigen vaccine for the prevention of Hepatitis B in adults in the United Kingdom . Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. doi: 10.1016/j.jval.2022.09.782
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C , Wilson M . Estimating the historical population-level impact of PCV13 national immunization programs on invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States . Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C , Wilson M . Non-vaccine serotype population-level trends for invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States . Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.